Syntara
35
0
1
30
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
11.4%
4 terminated/withdrawn out of 35 trials
88.2%
+1.7% vs industry average
17%
6 trials in Phase 3/4
10%
3 of 30 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (35)
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Role: lead
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
Role: lead
A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
Role: lead
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis
Role: lead
A Two-part Pharmacokinetic Study of PXS-5382A in Healthy Adult Males
Role: lead
Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma
Role: collaborator
Mannitol Bronchoprovocation Challenge Ancillary Study/ACRN
Role: collaborator
The Leaky Lung Test
Role: collaborator
A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD
Role: lead
Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Role: lead
Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD
Role: lead
Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years
Role: lead
Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma
Role: lead
Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma
Role: lead
Efficacy of TPI ASM8 During a 14-Day Allergen Challenge
Role: lead
A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma
Role: lead
Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma
Role: lead
Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients
Role: lead
Multiple Dose ASM8 in Mild Asthmatics
Role: lead
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
Role: lead